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Abstract: The establishment of the beneficial interactions between the host and its microbiota is 
essential for the correct functioning of the organism, since microflora alterations can lead to many 
diseases. Probiotics improve balanced microbial communities, exerting substantial health-
promoting effects. Here we monitored the molecular outcomes, obtained by gut microflora 
modulation through probiotic treatment, on human urine and serum metabolic profiles, with a 
metabolomic approach. Twenty-two subjects were enrolled in the study and administered with two 
different probiotic types, both singularly and in combination, for 8 weeks. Urine and serum samples 
were collected before and during the supplementation and were analyzed by nuclear magnetic 
resonance (NMR) spectroscopy and statistical analyses. After eight weeks of treatment, probiotics 
deeply influence the urinary metabolic profiles of the volunteers, without significantly altering their 
single phenotypes. Anyway, bacteria supplementation tends to reduce the differences in metabolic 
phenotypes among individuals. Overall, the effects are recipient-dependent, and in some 
individuals, robust effects are already well visible after four weeks. Modifications in metabolite 
levels, attributable to each type of probiotic administration, were also monitored. Metabolomic 
analysis of biofluids turns out to be a powerful technique to monitor the dynamic interactions 
between the microflora and the host, and the individual response to probiotic assumption. 
Keywords: probiotics; metabolomics; nuclear magnetic resonance spectroscopy; gut microflora 
 
  
Metabolites 2020, 10, 396 2 of 18 
 
1. Introduction 
The human gut normally hosts around 1000 different species of bacteria for a total of 1014 
commensal microorganisms; approximately 1.3 times more than the number of eukaryotic cells 
constituting the human body [1–3]. The majority of these are strict anaerobes which outnumbers 
those facultative and aerobic by approximately 2–3 orders of magnitude [4].  
The whole bacterial genome, the so-called intestinal microbiome (or “microbe” organ: 200 g in 
weight [5]), contains more than 5 million genes, a number that is 100-fold higher than the number of 
human genes [6]. 
The large arsenal of microbial genes provides a diverse range of biochemical and metabolic 
activities to complement host physiology and affect the hosts through huge benefits. The microbiota 
is essential for the development and correct functioning of the gut, helping the development of 
intestinal microvilli, and it is necessary for the development of the immune system. They are also 
involved in the digestion of polysaccharides and in the production of essential vitamins [7]. 
Moreover, they promote angiogenesis, regulate fat storage and protect against potential 
opportunistic pathogens [8]. So, the human body can be considered as a “superorganism”, with the 
gut microbiota collectively acting as a major virtual organ that contributes to host’s metabolism and 
physiology [9]. 
To ensure its crucial role in health promotion, the gut microflora composition normally 
undergoes constant and rapid changes, both in the structure and in the function, according to age, 
general conditions, lifestyle, diet habits, hygiene preferences or antibiotics intake [10]. Conversely, 
when the microflora is drastically altered, the well-being of many human niches can be compromised, 
leading to many chronic and degenerative diseases [11–13]. Accordingly, the establishment and 
preservation of beneficial interactions between the host and its associated intestinal microbiota are 
key requirements for an optimal psycho-physical state promotion. In this context, probiotics are 
increasingly used, with the final aim of manipulating the composition of the gut microbiota, 
improving balanced microbial communities, and thus exerting substantial health-promoting effects 
to the host [14–17]. Probiotics are “live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host” [17–19]. It must be underlined that, beyond composition, 
much of the impact of the bacterial communities on humans is carried out through the production 
and/or transformation of several metabolites, including amino acids, fatty acids, bile acids, hormones 
and vitamins [7]. Thus, in order to better understand how probiotic interventions influence the host, 
the analysis of the microbial communities should always be complemented by metabolomic analysis 
[20,21]. 
One of the main findings of metabolomics is that systemic biofluids like blood, urine and saliva, 
contain a strong individual metabolic signature, called metabolic phenotype or metabotype, which is 
stable over time, allowing us to monitor individual status and response to different stimuli [22–27], 
as well as to fingerprint several different diseases [28–33]. The metabotype is a multifactorial entity; 
in fact, besides being a snapshot of the subject’s genotype and metabolism, it is also influenced by 
many other factors, like gut microbiota, diet, lifestyle, drugs, etc. [34]. So-called bioactive food also 
impacts the human metabolome [35]. The influence of gut microbiota on the metabotype is 
particularly strong in the case of urine [36,37]. Under this light, the human metabolic phenotype could 
prove to be a very accurate and dynamic mirror, not only of the human organism, but, more correctly, 
of the “superorganism” and of its functioning and adapting processes [38–40]. 
In the present study, 1H nuclear magnetic resonance (NMR) spectroscopy has been used to 
explore and characterize the metabolic changes induced in the urine and serum metabotypes of 22 
healthy adult volunteers by the regular administration of probiotics.  
1H-NMR-based metabolomics could be a powerful technique to gain a deep insight on the 
molecular mechanisms and effects of the dynamic interactions between the commensal microflora 
and the host, and of the response to probiotic assumption.  
The probiotics used in the present study were Lactobacillus delbrueckii subs. delbrueckii (LDD01 or 
L here after) and a mix of five biotypes of Bifidobacterium longum (DLBL07 to DLBL11, DLBL or B here 
after). The two different supplementations were singularly administered in the first 4–6 weeks of the 
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experimental trial, and together in the subsequent 4–6 weeks. Univariate and multivariate statistical 
analyses have been used to evaluate the 1H-NMR urine and serum spectra acquired, and to 
characterize the individual effects of the treatment.  
2. Results 
2.1. Study Design 
The main features of the analyzed cohorts and collected samples are described in the Materials 
and Methods section and the Participation Flowchart is reported in Figure S1. 
The study was based on three different time frames (Figure 1A): 
Phase I (baseline, BL). A period of 4–6 weeks during which the volunteers did not take any 
probiotics. They proceeded with their usual diet and lifestyle without any standardization imposed. 
Twenty urine samples were collected from each volunteer (1 sample a day, excluding the weekend 
and the menstrual cycle days). At the end of phase I, a serum sample from each subject was also 
collected. 
Phase II (single probiotic administration, SP). A period of 4-6 weeks during which the volunteers 
were randomly divided into two groups, named “L + LB” and “B + BL”. The “L + LB” group (10 
subjects) added to their usual diet a daily dose of 1 billion of freeze-dried LDD01 probiotics, whereas 
the other group (“B + BL” group, 12 individuals) was supplemented with a daily dose of 1 billion of 
the DLBL mix. Again, 20 urine samples were collected as previously described. At the end of phase 
II, a serum sample from each subject was also collected. 
Phase III (coupled probiotic administration (CP) or wash-out (WO)). In the last period of 4–6 
weeks, 18 volunteers added both 1 billion of LDD01 and 1 billion of DLBL, together, to their usual 
diet. Thus, “L + LB” group (8 subjects) added 1 billion of DLBL to the daily dose of LDD01 and “B+BL” 
group (10 subjects) added 1 dose of LDD01 to the daily dose of DLBL.  
Three volunteers (two from the L + LB group and 1 from the B+BL group) performed this phase 
as a wash-out phase (WO) during which they did not assume any probiotics. Again, 20 urine samples 
were collected from each volunteer. At the end of phase III, a serum sample from each subject was 
also collected. 
Twenty-two volunteers performed the first and the second phase of the study. Of these, 18 
subjects completed the third phase as coupled probiotic administration, while three subjects as wash-
out; one volunteer did not perform the third phase (Figure 1B). 
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Figure 1. Experimental scheme. (A) Experimental scheme of the three phases of the project. (B) Table 
of the subjects that participated in the project in “L + LB” group and in “B + BL” group. 
2.2. Influence of Probiotic Treatment on Individual Urine Metabolic Phenotype 
In 2015, our research group demonstrated that the metabolic phenotype, based on the NMR 
spectral profiles of urine samples, is specific to each individual and stable over a time frame of 10 
years, in the absence of physio-pathological stressful conditions [24]. We also established that 
multivariate statistical analysis of multiple urine samples of individuals permits one to define their 
placement in the “metabolic space”, where each subject can be discriminated from the others with an 
accuracy close to 100% (97–98%) [22–24]. Here, we applied the same statistical analysis (principal 
component analysis (PCA)- canonical analysis (CA)- K-nearest neighbors (KNN)) used in our 
previous studies to characterize the urine individual metabolic phenotype of the volunteers, and to 
investigate if after probiotics assumption the individual phenotype significantly changes as a 
consequence of gut microflora modulation. 
As expected [22,23,41], the daily intra-individual differences were by far smaller than the inter-
individual separation, allowing individual discrimination: considering all samples collected in phase 
I, the individual discrimination was almost perfect, with an error of only 3% (Figure 2A). Phase I was 
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designed to establish a baseline reference for each volunteer in comparison with phase II and III, 
where effects of probiotic administration could be visible. 
The error in the individual discrimination increased slightly (6%) within samples collected 
during phase II (Figure 2B); however, the slight increase with respect to phase I is statistically 
significant. Interestingly, within samples collected in phase III, a further significant increase of the 
error in the individual discrimination up to 10% was observed (Figure 2C). 
Thus, probiotics administration influences the individual metabotype: upon administration of 
the same probiotics, individuals moved closer to one another in the phenotypic space. Nevertheless, 
they remained well discriminated from each other, and the effects were not so strong as to hamper 
the individual recognition. 
 
Figure 2. Urinary individual metabolic phenotype of the volunteers in (A) phase I (B) phase II (C) 
phase III. The score plots of PCA-CA-KNN individual discrimination are reported: each color 
represents a different volunteer, while each dot of the same color represents a different urine sample 
belonging to the same volunteer. PRB01: aquamarine; PRB02: red; PRB04: deep pink; PRB06: yellow; 
PRB07: light sky blue; PRB09: green; PRB10: purple; PRB11: gray; PRB12: orange; PRB 13: black; 
PRB14: gold; PRB15: cornflower blue; PRB16: brown; PRB17: light pink; PRB18: medium blue; PRB21: 
salmon; PRB23: dark yellow; PRB24: steel blue; PRB26: orchid; PRB27: dark orchid; PRB28: cyan; PRB 
29: forest green. (D) Values of individual discrimination errors (PCA-CA-KNN individual 
discrimination), for “L + LB” group and “B + BL” group, separately, in phase I, in phase II and in 
phase III. 
Considering “L + LB” group and “B + BL” group separately, the error in the individual 
discrimination using samples collected in phase I is always very low, around 3% for both (Figure 2D). 
For “L + LB” group, the individual discrimination error remained around 3% within phase II, whereas 
it increased considering samples of phase III (7%). On the contrary, in the case of “B + BL” group, the 
error in the individual discrimination increased from phase I (3%), to phase II (6%) and to phase III 
(11%) (Figure 2D).  
The increment of the discrimination error among volunteers seems to be related to the 
administration of DLBL more than LDD01. Subjects of “B + BL” group were administered with DLBL, 
both in phase II and in phase III, whereas in “L + LB” group the volunteers assumed DLBL only in 
phase III. According to this, in “B + BL” group, the error in the individual discrimination started to 
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increase from phase II and the effect became higher in phase III, whereas, in “L + LB” group, the error 
in the discrimination increased only in phase III.  
2.3. Individual Urine Effects of Probiotic Administration 
To underline the overall outcomes of probiotics assumption, the urine samples, collected during 
the three phases of the study, were compared using multilevel partial least squares (M-PLS) analysis 
(Figure 3). A multilevel approach was chosen to suppress the noise due to intra-individual variability, 
i.e., each individual acts as control for him/herself. The resulting accuracy explains how much the 
groups (and so the individual urine profiles) changed after the treatments. The application of M-PLS 
analysis resulted in a modest discrimination between samples collected in phase I and II, with a 
discrimination accuracy value of 85%, considering all the individuals together (Figure 3A,C). The 
discrimination accuracy became high, 95%, considering the comparison between urine samples of 
phase I and phase III, and a better separation of the two groups was achieved (Figure 3B,C). 
 
Figure 3. Score plots of M-PLS discrimination of the comparison between urine samples collected 
during (A) phase I (red spheres) and phase II (green spheres); (B) during phase I (red spheres) and 
phase III (blue spheres). (C) Discrimination accuracy values for the three pairwise comparisons 
among phase I, phase II and phase III, for all samples together, “L + LB” group and “B + BL” group. 
The median spectrum of each subject in each phase was calculated and used to build the MPLS 
models. 
Furthermore, each subject has also been considered separately, and PCA-CA-KNN was used to 
identify individual behaviors because of the probiotic intake (Table 1). From the obtained results, it 
was possible to identify two different effects on metabolic phenotypes: (i) in some subjects (i.e., 
PRB09, PRB14, PRB13) the discrimination accuracies between phase I and phase III remained the 
same (or slightly increased) with respect to the comparisons between phase I and phase II; according 
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to this, there is a weak or even no discrimination between the samples of phase II and phase III 
(accuracy around 55–70%). This could mean that, for these subjects, 4–6 weeks (time length of phase 
II) are enough to have marked effects of probiotics on the metabolic profiles; subsequent probiotics 
administration in phase III did not alter more the metabolic profile.  
(ii) Contrarily, in other subjects (i.e., PRB21, PRB17, PRB10) the discrimination accuracies 
gradually increased from the comparison between phase I vs. phase II and phase I vs. phase III. For 
these subjects, more time seemed to be needed to stabilize the metabolic effects of probiotic 
assumption, and phase III is crucial to have marked effects.  
In both cases, the discrimination accuracies for the comparison of phase I vs. phase III were very 
high for most of the volunteers. These data underlined that the effects of the treatment were strongly 
individual-dependent. 
Table 1. PCA-CA-KNN discrimination values for all the pairwise comparisons among phase I, phase 
II and phase III, for all the subjects individually.  
“L + LB” Group “B + BL” Group 


















Subject: % % % Subject: % % % 
PRB01 78 72 81 PRB10 65 68 85 
PRB02 68 60 83 PRB11 73 83 85 
PRB04 80 84 95 PRB12 58 50 68 
PRB06 88 65* 91* PRB13 83 61 92 
PRB07 63 57 82 PRB15 75 67 75 
PRB09 83 59 85 PRB17 84 72 99 
PRB14 80 62 89 PRB18 78 73* 86* 
PRB16 85 67 85 PRB21 72 74 89 
PRB24 78 57* 83* PRB23 70 -- -- 
PRB26 65 62 82 PRB27 56 73 80 
 
   
PRB28 68 74 73 
 
   
PRB29 74 98 97 
Individuals that performed phase III as a wash-out are marked with *. 
PRB06, PRB18, PRB24 performed phase III as a wash-out. Looking at their values of 
discrimination accuracies (Table 1), it can be concluded that the spectra of the urines collected in 
phase III remained more or less similar to those collected during phase II. It is possible to speculate 
that 4–6 weeks (time length of wash-out) were not enough to revert the effects introduced from 
probiotics assumption during phase II, thus suggesting a possible long-lasting intestinal colonization 
by the probiotic microorganisms. 
To better illustrate the individual effects on metabolic profiles introduced by the daily 
consumption of probiotics, for each individual, the 20 spectra of urine samples collected in phases I, 
II and III, were considered as originating from different individuals (pseudo-individuals) [23]; 
therefore, each subject gives rise to three different pseudo-individuals (Figure 4).  
Forty-four pseudo-individuals were created for the comparison of phase I vs. phase II. PCA-CA-
KNN was used to determine the individual discrimination accuracies and errors and the confusion 
matrix is reported in Figure 4A. Again, two different behaviors can be detected. Some pseudo-
individuals (belonging to the same volunteer) are relatively well discriminated from one another, 
with a discrimination accuracy of up to 75% (and an error less than 25%); they were recognized as 
two distinct individuals, indicating that the probiotic treatment introduced effects on their metabolic 
profiles. On the contrary, other pairs of pseudo-individuals were not discriminated from one another 
(discrimination error around 40–50%); they were recognized as the same individual, indicating that 
a period of 4–6 weeks of probiotics assumption (phase II) was not sufficient to establish clear 
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differences. It is to be noted that these values of discrimination accuracies agree with those of 
discrimination accuracies reported in Table 1.  
For the comparison between phases I and III, 42 pseudo-individuals were created (42, and not 
44, pseudo-individuals were created because subject “PRB 23” had been eliminated from the analysis 
because he/she did not undergo the phase III probiotic administration). In this comparison, most 
pseudo-individuals couples originating from the same individual were very well discriminated from 
one another (Figure 4B). It is possible to note that, in this last case, the pseudo-individuals that have 
the lowest values of discrimination errors (highest values of discrimination accuracy) are those 
created with samples collected in phase I. On the contrary, the corresponding pseudo-individuals 
created with samples collected during phase III have higher values of discrimination error between 
one another. These data agree with the higher error in the individual discrimination obtained using 
only urine spectra belonging to samples collected in phase III (Figure 2). 
 
Figure 4. (A) Level plot of the confusion matrix of PCA-CA-KNN discrimination of 44 pseudo-
individuals created for the comparison between phase I and II. (B) Level plot of the confusion matrix 
of PCA-CA-KNN discrimination of 42 pseudo-individuals created for the comparison between phase 
I and III. 
2.4. Urine Metabolite Analysis 
A set of 40 urine metabolites, whose peaks in the spectra were well defined and isolated, were 
selected and their level analyzed.  
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Five metabolites resulted to be significantly different (p < 0.05), at least in one pairwise 
comparison among phase I, phase II and phase III, considering all the individuals together (Table 2). 
Citrate, creatinine and 1-methylnicotinamide (mNam) were among the metabolites that showed 
significant changes (p < 0.01). Specific effects attributable to the type of probiotic have been also 
detected analyzing the subjects of “L + LB” group and “B + BL” group separately (Table 2). 
Table 2. Urine metabolites that showed significant concentration changes at least during one phase 














Leucine 0.020 0.10 0.656 −0.03 0.222 0.07 
Isoleucine 0.057 0.11 0.351 0.03 0.004 0.13 
Valine 0.041 0.11 0.945 −0.01 0.079 0.10 
Citrate 0.040 0.10 0.731 0.04 0.013 0.14 
Creatinine 0.041 0.07 0.374 0.01 0.003 0.08 
Choline 0.228 0.01 0.521 −0.06 0.013 −0.05 
1-methylnicotinamide 0.185 0.03 0.083 0.01 6.32*10−5 0.04 
Malonate 0.001 0.05 0.351 0.01 1.27*10−5 0.06 
Valerate 0.040 0.03 0.858 −0.02 0.079 0.02 
2-hydroxyisobutyric 0.358 0.14 0.351 −0.01 0.019 0.13 
Acetoacetate 0.042 0.06 0.771 0.04 0.032 0.1 
Fucose 0.178 0.05 0.374 0.02 0.021 0.07 
Induxylsulfate 0.180 0.20 0.374 −0.12 0.004 0.08 
Methanol 0.239 -0.1 0.008 −0.21 6.42*10−5 −0.31 
Dimethylglycine 0.013 0.25 0.848 −0.04 0.008 0.21 
Acetone 2.71*10−5 0.25 0.351 −0.09 0.013 0.16 
Glycolate 0.042 0.46 0.752 −0.15 0.309 0.31 
Ornithine+arginine-acetate 0.021 0.10 0.666 −0.03 0.001 0.07 
4-hydroxyhippuricacid 0.586 0.17 0.376 0.14 0.041 0.31 













Leucine 0.026 0.12 0.622 −0.05 0.359 0.07 
Valine 0.025 0.16 0.622 −0.05 0.152 0.1 
Citrate 0.071 0.09 0.466 0.07 0.012 0.16 
Creatinine 0.071 0.07 0.622 0.03 0.042 0.010 
Choline 0.135 0.03 0.466 0.03 0.001 0.06 
1-methylnicotinamide 0.386 0.004 0.466 0.04 0.012 0.045 
Malonate 0.059 0.06 0.925 −0.001 0.043 0.05 
Induxylsulfate 0.984 0.036 0.466 0.18 0.043 0.22 
Dimethylglycine 0.105 0.15 0.798 0.07 0.044 0.22 
Acetone 0.021 ↑0.22 0.622 −0.02 0.127 0.19 
Glycolate 0.026 ↑0.74 0.466 −0.5 0.273 0.24 
Ornithine + arginine + acetate 0.091 0.09 0.834 −0.004 0.043 0.1 













Isoleucine 0.282 0.12 0.282 0.02 0.033 0.14 
Creatinine 0.281 0.07 0.282 0.003 0.036 0.07 
Formate 0.860 0.08 0.860 −0.01 0.033 0.07 
1-methylnicotinamide 0.517 0.05 0.517 −0.01 0.009 0.04 
Malonate 0.038 0.04 0.038 −0.01 0.0001 0.03 
Methanol 0.281 −0.1 0.282 −0.25 0.0001 −0.36 
Acetone 0.005 0.28 0.005 −0.16 0.086 0.11 
Erythritol 0.158 0.27 0.158 0.50 0.009 0.77 
Ornith-arginine-acetate 0.236 0.11 0.236 −0.05 0.032 0.06 
4-hydroxyhippuricacid 0.302 0.24 0.302 0.13 0.033 0.37 
In the table the p-values obtained using false discovery rate (FDR) correction method and log2 (fold 
change) (FC) values are reported. Positive FC: increment; negative FC: decrement (in the second 
group of each comparison with respect to the first). 
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The citrate concentration, whose levels correlate with those of calcium-citrate complexes, 
metabolic acidosis and the reduction of calcium/magnesium ions, increased in phase II in “L + LB” 
group; these higher levels were maintained (or even increased) also in phase III. Creatinine 
concentration, the degradation product of creatine, significantly increased in phase II only in “L + 
LB” group where the individuals were supplemented with LDD01. In this group, in phase III, 
creatinine concentration remained stable at the highest levels reached in phase II. Instead, in “B + BL” 
group, the concentration of this metabolite increased in a significant way only in phase III, when the 
volunteers added a daily dose of LDD01 together with the assumption of DLBL. So, the higher levels 
of creatinine seem to be attributable more to the effects of LDD01 administration rather than of DLBL. 
Moreover, in both groups, the levels of the niacin microbial metabolite mNam increased in phase II, 
but they became higher, and statistically significant, only in phase III, where the volunteers were 
administered with both probiotics together. This effect was stronger in “L + LB” group rather than in 
“B + BL” group. 
In “L + LB” group, leucine, an essential amino acid for human well-being, presented higher 
concentration values in phase II than in phase I but, when the volunteers were administered with 
both probiotics together (phase III), its level decreased toward the reference value of phase I. This 
metabolite had the same trend during the three phases in “B + BL” group, but not in a significant 
way. Finally, in the same group, formate, key metabolite at the interface between the host and the 
microbiome metabolism, decreased its concentration in phase III. 
2.5. Serum Metabolite Analysis 
1H-NMR NOESY (Nuclear Overhauser Effect Spectroscopy) spectra of serum samples, collected 
at the end of each phase, were compared using M-PLS to check overall effects of probiotics 
assumption in blood. As in the case of urine, a multilevel approach has been used to suppress the 
noise introduced by the intra-individual variability [42]. In the case of serum samples, no 
discrimination was obtained between phase I and II (55%) (Figure 5A). The discrimination slightly 
increased (accuracy of 62%) when comparing samples belonging to phase I and phase III (Figure 5B). 
 
Figure 5. Score plot of M-PLS discrimination of serum samples collected during (A) phase I (red 
spheres) and phase II (green spheres); and (B) phase I (red spheres) and phase III (blue spheres). (C) 
Discrimination accuracy values for the three pairwise comparisons among phase I, phase II and phase 
III. 
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Twenty-four metabolites, that are normally present in serum, and whose peaks in the CPMG 
spectra were well defined and isolated, were assigned and analyzed. Five of them resulted with 
significantly different concentration levels (p < 0.05), in at least one pairwise comparison among phase 
I, phase II and phase III (Table 3). Among them, pyruvate, phenylalanine and proline were the 
metabolites that showed the lowest p-values (p < 0.02) in both groups.  















proline 0.018 0.32 0.886 0.02 0.014 0.34 
pyruvate 0.078 0.41 0.292 0.25 0.0006 0.65 
dimethylglycine 0.046 −0.33 0.755 0.20 0.656 −0.13 
phenylalanine 0.018 0.23 0.806 0.001 0.0006 0.23 













pyruvate 0.209 0.46 0.762 0.31 0.033 0.77 




p-values, obtained using FDR correction method and log2 (fold change) (FC) values are reported. 
Positive FC: increment; negative FC: decrement (in the second group of each comparison with respect 
to the first). 
Pyruvate was the only metabolite whose concentration tended to increase during both phase II 
and phase III; while the increment is not statistically significant between phase I and II, it became 
more evident and significant when comparing phase I and III. Looking at the two groups separately, 
in “L + LB” group, the increment of the pyruvate levels, even not statistically significant, is visible 
only in phase III where the volunteers were administered with both probiotics (data not shown), 
whereas in “B + BL” group, the increased levels of pyruvate started in phase II and increased 
significantly during phase III. From these data, it is possible to note that higher levels of pyruvate are 
more related to the daily administration of DLBL rather than of LDD01. In “B + BL” group, proline 
and phenylalanine concentration levels tend to increase from phase I, to phase II; in phase III, the two 
metabolites increased significantly with respect to phase I. Despite not being statistically significant, 
the trend to increase of these metabolites has also been detected in “L + LB” (data not shown). 
3. Discussion 
The aim of the present study was to monitor the molecular outcomes obtained by gut microflora 
modulation through probiotic treatment, on human urine and serum metabolic profiles with a 1H-
NMR-based metabolomic approach. To achieve this purpose, the human metabolome of 22 healthy 
individuals was monitored during probiotics administration.  
We showed that the probiotic supplementation could influence the urine metabolic profiles of 
the volunteers, without altering in a substantial way the metabotypes of each individual.  
It was previously demonstrated that obtaining a strong predictive model for the individual 
metabolic phenotype relies on the analysis of a sufficient number of urine samples from the same 
individual collected on different days. Twenty urine samples are enough to minimize the “metabolic 
noise” of the day-to-day variability and achieve a very good individual discrimination, with an error 
around 2–3%. A lower error, about 1%, can be obtained using as many as 40 urine samples per person 
[22–24]. Similar results can be obtained using multiple urine samples collected in the same day (4–5 
per day, for 10 days) [27]. Interestingly, using the spectra of samples collected in phases II and III, the 
individual discrimination errors (6% and 10%, respectively) were significantly higher than those 
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obtained and expected using samples collected in phase I (3%), where no effects attributable to 
probiotics assumption were present (Figure 2). This effect seems to be stronger in “B + LB” group, 
where individuals were administered with DLBL from the beginning of phase II (Figure 1).  
Our data could be interpreted as an indication that the urine metabotype building blocks arising 
from the activity of the microbiome contribute to 8–10% of the intra-individual metabotype 
variability; this component tends to become similar among all the volunteers after 8–12 weeks of daily 
consumption of probiotics, slightly decreasing intra-individual variations. The effect of probiotic 
assumption (in particular for DLBL) seems to affect the metabolic phenotypes, but not so strongly as 
to hamper the individual recognition. This hypothesis was also confirmed by the pseudo individuals’ 
analysis (Figure 4). 
By suppressing the intra-individual variability using a multilevel approach, it was possible to 
detect general effects of probiotics assumption in the urine spectra: samples collected during phase I 
were discriminated from samples collected during phase II, with an accuracy of 85%. The accuracy 
value became 95% considering the comparison between phase I and III (Figure 3). This means that, 
after 8–12 weeks, the effects of probiotics assumption become stronger and more detectable. This can 
be due to three different and interacting reasons: (i) build-up of probiotic abundance in time during 
the supplementation (from 4–6 weeks in phase II to 8–12 weeks in phase III), (ii) higher daily dosage 
(from 1 billion of probiotics per day in phase II, to two billion per day in phase III), (iii) possible 
synergistic interactions between LDD01 and DLBL. Anyway, the effects are individual-dependent. 
In some individuals, robust effects are already well visible at the end of phase II, after the daily 
assumption of LDD01 or DLBL; for others, instead, strong effects are visible only in phase III. Even 
in the case where the effects were well visible at the end of phase II, phase III further contributed to 
increase the accuracy for the recognition between pre- and post-probiotic assumption.  
Modifications in metabolite levels, attributable to the administration of probiotic, could be due 
to a different food degradation and digestion by the bacteria, to the increased availability of 
metabolites, or to a direct effect of bacteria on the gut. Some of the alterations can be foreseen as 
positive effects on general health; others could be considered as dangerous, others of uncertain effect. 
In urine spectra, citrate, creatinine and mNam were among the metabolites that showed significant 
changes (p < 0.01) after the probiotic assumption (Table 2).  
Citrate in both groups increased in phase II and remained at a higher level in phase III. This 
metabolite in the urine has a very important role due to its inhibitory action in calcium stone 
formation [43]. Patients with calcium stones are characterized by low urinary citrate excretion; the 
normalization of citrate urinary concentration in this case resulted in a significant inhibition of crystal 
growth [44,45]. 
mNam has been found to increase especially in phase III; the assumption of LDD01 could be 
considered the main factor responsible of this phenomenon, because mNam was higher in volunteers 
who had been administered with LDD01 for a longer time (“L + LB” group). Until recently, mNam 
has been thought to be a biologically inactive product of nicotinamide metabolism (vitamin B3) in the 
pyridine nucleotides pathway [46]. Increased levels of this metabolite have also been found in the 
urine of adult mice treated with Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 [47]. 
mNam is involved in the pathway of NAD synthesis, and an increase of NAD production can prevent 
age-related diseases [47]. 
Our data show that LDD01 supplementation increased the excretion rate of creatinine, a urinary 
metabolite derived from creatine. In fact, in “L + LB” group, higher levels of creatinine were present 
in samples collected during phases II and III; in “B + BL” group, an increase of this metabolite was 
detected only in phase III. Higher levels of creatinine and urea in blood can be considered as markers 
of renal failure. In fact, several in vivo and in vitro studies show that probiotics, especially mixtures 
of Lactobacilli, are able to decrease blood levels of urea, creatinine and other markers of kidney 
diseases [48].  
Serum (or plasma), at variance with urine, is less affected by circadian variations. Due to this 
important systemic role, in the blood, the metabolite concentrations are strongly controlled through 
all cycles used for setting and maintaining equilibrium conditions. For these reasons, although some 
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effect and interaction of the microbiome has also been characterized on blood metabolites and 
biochemistry [49], strong effects on the serum multivariate profile, attributable to probiotics 
administration, were not expected. Although no discrimination has been obtained in the multivariate 
analysis, that univariate revealed some metabolite changes in the serum of the volunteers during the 
study. In serum spectra pyruvate, phenylalanine and proline were the metabolites with significant 
changes (p < 0.02) in both groups (Table 3). Phenylalanine and proline showed the same trend along 
the three phases: in both groups, they increased from phase I to phase II, and the higher levels were 
maintained also during phase III. Phenylalanine is a potent cholecystokinin releaser, and it can slow 
down gastric emptying. High levels of this amino acid were also found in plasma mice after the 
administration of Lactobacillus rhamnosus [50]. In the same study, also proline, a non-essential amino 
acid in mammals with several key functions for human health [51], was increased due to the action 
of probiotics. Moreover, using in vivo approaches, after the assumption of L. rhamnosus, proline level 
became normal in alcoholic fatty liver disease mice [52].  
The levels of pyruvate in sera increased after probiotic assumption in both groups. Pyruvate 
performs many functions in human metabolism, and it is an important intermediate in the production 
of ATP. Some pathologies, mostly neurodegenerative, involve an unbalanced pyruvate metabolism 
[53]. We can speculate that the use of these probiotic strains could be beneficial for the modulation of 
pyruvate excretion in these kinds of diseases.  
The systematic assumption of probiotics can modulate some important functions on humans 
that have to be understood more deeply. Several in vivo studies have shown that probiotics can 
modulate the gut microflora in order to promote health and prevent, in particular, gastrointestinal 
and renal diseases. In humans, the situation is more complicated due to different genetic backgrounds 
and different metabolic variations. In fact, our results show that the response to probiotics is strongly 
individual-dependent and it could be related to genetic and environmental factors. Some metabolites 
that are mainly linked to the prevention and treatment of gastrointestinal and renal diseases and to 
keeping cells active by increasing biosynthesis of ATP and proteins [54] change in a significant way 
as a consequence of specific probiotics administration.  
To our knowledge, this is one of the first studies combining the effects of probiotic 
administration on healthy human metabolism, with the possibility to characterize these effects by 
using 1H-NMR spectroscopy. 
4. Materials and Methods 
4.1. Recruitment of Volunteers and Exclusion Criteria 
The trial was registered at clinical.trials.gov with the registration number NCT04506385. 
Twenty-two adult healthy individuals, 9 females and 13 males, between 24 and 62 years of age were 
recruited for this study. Exclusion criteria included previous surgery on the intestinal tract, 
probiotic/prebiotic and antibiotic treatments within 3 and 1 months, respectively, before the 
beginning of the study. In addition, subjects were excluded from the study if they were going to 
drastically change their diet or lifestyle during the study. 
All subjects gave their informed consent for the inclusion in the study. The study was conducted 
in accordance with the Declaration of Helsinki, as revised in 2013. Ethical approval (protocol n° 
294/CE, study n° CE 14/20, International Ethics Committee A.O.U. “Maggiore della carità”, Novara, 
Italy) or the study protocol was obtained. 
4.2. Probiotic Formulation 
The probiotic formulation named “LDD01” (batch R&S 0342-03, Probiotical S.p.A, Novara, Italy) 
contained a freeze-dried mixture > 1 × 109 CFU/sachet L. delbrueckii subsp. delbrueckii MB386 (LDD01; 
DSM 22106) and 2.5 g of maltodextrin. The probiotic formulation named “DLBL” (batch R&S 0342-
01, Probiotical S.p.A., Novara, Italy) contained a freeze-dried bacterial mixture > 1 × 109 CFU/sachet 
of B. longum DLBL07 (DSM 25669; Leibniz Institute DSMZ- German Collection of Microorganisms 
and Cell Cultures, GmbH), B. longum DLBL08 (DSM 25670), B. longum DLBL09 (DSM 25671), B. 
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longum DLBL10 (DSM 25672), B. longum DLBL11 (DSM 25673) and 2.5 g of maltodextrin. Probiotic 
formulations were stored at 4 °C until use. 
4.3. Sample Collection 
All the samples were collected and processed according to standard operating procedures 
(SOPs) to obtain high quality samples for metabolomics [55–57]. Both serum and urine were collected 
under fasting condition. For urine, the midstream of the first urine of the morning was collected. All 
the processing procedures are detailed in Takis at al. [20]. During the course of the study, the samples 
were stored at −80 °C in the repository of the Da Vinci European Biobank, which offered a 
conservation service (daVEB, DOI:10.5334/ojb.af, https://www.unifi.it/vp-11370-da-vinci-european-
biobank.html, Italy) [58,59].  
4.4. NMR Analysis and Spectral Processing 
NMR samples were prepared according to SOPs for urine and serum [20,21,60]. All the 
procedures for NMR sample preparation and analysis are detailed in Vignoli et al. [21]. Briefly, 
samples were analyzed using 4.25 mm NMR tube (Bruker BioSpin Gmbh, Rheinstetten, Germany). 
One-dimensional (1D) 1H-NMR spectra were acquired using a spectrometer operating at 600 MHz 
(Bruker BioSpin) optimized for metabolomics, equipped with a 5 mm triple resonance inverse (TCI) 
cryoprobe (CP)  1H-13C-31P and 2H-decoupling cryoprobe, including a z axis gradient coil, an 
automatic tuning-matching and an automatic sample changer. Samples were kept for 3 min inside 
the NMR probe head for temperature equilibration (300 K for urine and 310 K for serum). 1H-NMR 
spectra were acquired with water peak suppression and (i) a standard NOESY pulse sequence, for 
both urine and serum samples; (ii) a standard Carr–Purcell–Meiboom-Gill (CPMG) pulse sequence, 
for serum samples.  
Free induction decays were multiplied by an exponential function equivalent to a 1.0 Hz line-
broadening factor, before applying Fourier transform. Transformed spectra were automatically 
corrected for phase and baseline distortions and calibrated to the reference signal of TMSP at δ 0.00 
ppm, and to the glucose doublet at δ 5.24 ppm, for urine and serum respectively, using TopSpin 3.5 
(Bruker BioSpin Gmbh, Rheinstetten, Germany). 
4.5. Statistical Analysis 
Various kinds of multivariate statistical techniques were applied on the bucketed spectra. 
Bucketing was performed by segmenting each spectrum in the range between 0.2 and 10.00 ppm into 
0.02-ppm chemical shift regions (region between 6.0 and 4.5 ppm containing residual water signal 
was excluded). The corresponding spectral areas were integrated using AMIX software (Bruker 
BioSpin Gmbh, Rheinstetten, Germany). Individual-dependent probabilistic quotient normalization 
[32] was carried out on the obtained buckets prior to statistical analyses. 
Principal component analysis (PCA) was used to obtain a preliminary outlook of the data 
(visualization in a reduced space, clusters detection, screening for outliers). Partial least squares (PLS) 
and multilevel PLS (MPLS) [42] were employed to perform supervised data reduction and 
classification; canonical analysis (CA) was used in combination with PCA to increase the supervised 
separation of the analyzed groups. Accuracy, specificity and sensitivity were estimated according to 
standard definitions. The global accuracy for classification was assessed by means of a Monte Carlo 
cross-validation scheme.  
Univariate analyses of the NMR data were performed on Fourier transformed and calibrated 
spectra. Metabolites originating well defined and resolved peaks in the spectra were assigned and 
their levels were analyzed. The assignment was performed using an 1H-NMR spectra library of pure 
organic compounds, public databases, e.g., Human Metabolome Database, storing reference 1H-NMR 
spectra of metabolites, spiking 1H-NMR experiments and using literature data. The relative 
concentrations of each metabolite were calculated by integrating the signals in the spectra. The non-
parametric Wilcoxon-Mann-Whitney test was used for the determination of the meaningful 
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metabolites that changed in concentration during each of the three phases. False discovery rate 
correction was applied using the Benjamini and Hochberg method [61] (FDR): an adjusted p-value of 
0.05 was deemed significant.  
Supplementary Materials: The following are available online at www.mdpi.com/2218-1989/10/10/396/s1, Figure 
S1: participation Flowchart. 
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